Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethyl Fumarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Fumarate SCHEMBL1904369 | 1.00 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL9435698 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL5016627 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL11470776 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL6440837 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL1905731 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL1902730 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL1903287 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL20594713 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 | |
| Ethyl Fumarate SCHEMBL6440490 | 0.95 | HCAR2 (0.61) | HCAR2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016074684-A1 | FUMARIC ACID DERIVATIVES FOR MEDICAL USE | SYDDANSK UNIVERSITET (DK) | 2016-05-19 | — | — | WO | claimed |
| US-20160030374-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2016-02-04 | — | — | US | claimed |
| US-8980832-B2 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | BIOGEN IDEC INTERNATIONAL GMBH (CH) | 2015-03-17 | — | — | US | claimed |
| US-20110124615-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG | 2011-05-26 | — | — | US | claimed |
| US-20080233185-A1 | Fumaric Acid Derivatives as NF-kappaB Inhibitor | FUMAPHARM AG | 2008-09-25 | — | — | US | claimed |
| EP-1913942-A2 | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | Fumapharm AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-1663197-B1 | THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2007-12-05 | — | — | EP | claimed |
| US-20070027076-A1 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | FUMAPHAM AG | 2007-02-01 | — | — | US | claimed |
| EP-1248606-B1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES | FUMAPHARM AG (CH) | 2006-06-14 | — | — | EP | claimed |
| EP-1663197-A1 | THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | Fumapharm AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023241-A1 | THE USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2005-03-17 | — | — | WO | claimed |
| US-6858750-B2 | Use of fumaric acid derivatives for treating mitochondrial diseases | FUMAPHARM AG (CH) | 2005-02-22 | — | — | US | claimed |
| US-20040054001-A1 | Fumaric acid derivatives as nf-kappab inhibitors | FUMAPHARM AG (CH) | 2004-03-18 | — | — | US | claimed |
| US-20030013761-A1 | Use of fumaric acid derivatives for treating mitochondrial diseases | BIOGEN INTERNATIONAL GMBH (CH) | 2003-01-16 | — | — | US | claimed |
| WO-2016074684-A1 | FUMARIC ACID DERIVATIVES FOR MEDICAL USE | SYDDANSK UNIVERSITET (DK) | 2016-05-19 | — | — | WO | disclosed |
| US-20160030374-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FUMAPHARM AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-8980832-B2 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | BIOGEN IDEC INTERNATIONAL GMBH (CH) | 2015-03-17 | — | — | US | disclosed |
| US-6858750-B2 | Use of fumaric acid derivatives for treating mitochondrial diseases | FUMAPHARM AG (CH) | 2005-02-22 | — | — | US | disclosed |
| US-20040054001-A1 | Fumaric acid derivatives as nf-kappab inhibitors | FUMAPHARM AG (CH) | 2004-03-18 | — | — | US | disclosed |
| US-20030013761-A1 | Use of fumaric acid derivatives for treating mitochondrial diseases | BIOGEN INTERNATIONAL GMBH (CH) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054001-A1 | Fumaric acid derivatives as nf-kappab inhibitors | NFKBIA, NFKB1, NFKB2 | HCAR2 480/4885CA12 1740/4885CA1 640/4885 |
| US-20160030374-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FH, FAH, AADAC | HCAR2 44/4885CA12 1050/4885CA1 278/4885 |
| US-20080233185-A1 | Fumaric Acid Derivatives as NF-kappaB Inhibitor | NFKBIA, NFKB1, NFKB2 | HCAR2 485/4885CA12 1755/4885CA1 639/4885 |
| US-20070027076-A1 | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | FH, FAH, AADAC | HCAR2 44/4885CA12 1050/4885CA1 278/4885 |
| US-20030013761-A1 | Use of fumaric acid derivatives for treating mitochondrial diseases | FH, HADHA, HADH | HCAR2 1163/4885CA12 2834/4885CA1 1590/4885 |
| US-20110124615-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC INSUFFICIENCY, AND ASTHMA | FH, FAH, AADAC | HCAR2 44/4885CA12 1050/4885CA1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.